RA does not contribute to increased severity or progression of HCV-related liver disease and does not negatively affect the effectiveness or safety of DAA therapy. Liver disease stage and hepatic dysfunction, rather than the presence of RA, are the key determinants of treatment outcomes in patients with chronic HCV infection.
Brzdęk et al. (Mon,) studied this question.